Recruiting PHASE3 INTERVENTIONAL 4-arm NCT07253285

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity

Sponsor: Novo Nordisk A/S

Conditions Obesity Overweight

Interventions Cagrilintide Placebo cagrilintide Placebo semaglutide Semaglutide

Updated 3 times since 2025 Last updated: Jan 26, 2026 Started: Jan 8, 2026 Primary completion: Mar 20, 2030 Completion: Sep 20, 2033

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07253285, this PHASE3 trial focuses on Obesity and Overweight and remains actively recruiting participants. Sponsored by Novo Nordisk A/S, it has been updated 3 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jan 2026 — Feb 2026 [monthly]

Not Yet Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aalborg, Denmark , Amersfoort, Netherlands , Atlanta, United States , Baia Mare, Romania , Baltimore, United States , Bangalore, India , Bangkok, Thailand , Barcelona, Spain , Baton Rouge, United States and 93 more locations